-
公开(公告)号：EP1104440A1
公开(公告)日：2001-06-06
申请号：EP99918690.1
申请日：1999-04-20
发明人： BERGSMA, Derk , ELSHOURBAGY, Nabil , SHABON, Usman
IPC分类号： C07K14/705
CPC分类号： C07K14/723 , A61K38/00
摘要： AXOR-1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR-1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
-
公开(公告)号：EP1129101A1
公开(公告)日：2001-09-05
申请号：EP99972639.1
申请日：1999-11-17
IPC分类号： C07H21/02 , C07H21/04 , A61K48/00 , A61K49/00 , C12N15/00 , C12N15/63 , C12N15/86 , C12N5/02 , C12N15/85 , C12N5/00 , C07K14/00 , C07K16/00 , A01N37/18 , A01N61/00 , C12Q1/68 , C12Q1/00
CPC分类号： C07K14/705 , A61K48/00
摘要： AXOR15 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR15 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
-
公开(公告)号：EP1104483A1
公开(公告)日：2001-06-06
申请号：EP99935816.1
申请日：1999-07-22
发明人： ELSHOURBAGY, Nabil , SHABON, Usman
IPC分类号： C12P15/00 , C07K14/47 , C07K14/705
CPC分类号： C07K14/723 , A61K38/00
摘要： GPR31A polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing GPR31A polypeptides and polynucleotides in therapy, and diagnostic assays for such.
-
公开(公告)号：EP1189944A1
公开(公告)日：2002-03-27
申请号：EP00942952.3
申请日：2000-06-19
发明人： ELSHOURBAGY, Nabil , SHABON, Usman
IPC分类号： C07K14/705 , C07K16/28 , C12N15/12
CPC分类号： C07K14/705
摘要： The AXOR16 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR16 polypeptides and polynucleotides in diagnostic assays.
-
公开(公告)号：EP1073681A1
公开(公告)日：2001-02-07
申请号：EP99917624.1
申请日：1999-04-19
发明人： BERGSMA, Derk , ELSHOURBAGY, Nabil , SHABON, Usman
IPC分类号： C07K14/705
CPC分类号： C07K14/705
摘要： AXOR-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising AXOR-2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
-
公开(公告)号：EP1255814A1
公开(公告)日：2002-11-13
申请号：EP01903412.3
申请日：2001-01-29
IPC分类号： C12N5/10 , C12N15/12 , C12N15/63 , C12N15/64 , C07K14/705 , C07K14/71 , C07K14/715 , C07K14/72 , C07K16/18
CPC分类号： C07K14/723 , C07K14/705
摘要： AXOR36 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR36 polypeptides and polynucleotides in diagnostic assays.
摘要翻译： 公开了AXOR36多肽和多核苷酸以及通过重组技术生产这些多肽的方法。 还公开了在诊断测定中利用AXOR36多肽和多核苷酸的方法。
-
公开(公告)号：EP1212347A1
公开(公告)日：2002-06-12
申请号：EP00912077.5
申请日：2000-03-01
CPC分类号： C07K14/723 , C07K14/715
摘要： AXOR23 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR23 polypeptides and polynucleotides in diagnostic assays.
摘要翻译： 公开了AXOR23多肽和多核苷酸以及通过重组技术生产这些多肽的方法。 还公开了在诊断测定中利用AXOR23多肽和多核苷酸的方法。
-
8.发明公开HUMAN RECEPTOR GPR14, AND A METHOD OF FINDING AGONIST AND ANTAGONIST TO HUMAN AND RAT GPR14 审中-公开人类受体GPR14和方法用于搜索激动剂和拮抗剂人和大鼠GPR14受体
公开(公告)号：EP1056844A1
公开(公告)日：2000-12-06
申请号：EP99903409.3
申请日：1999-01-27
申请人： SMITHKLINE BEECHAM CORPORATION , SMITHKLINE BEECHAM PLC , Smithkline BeechamLaboratoires Pharmaceutiques
发明人： DOUGLAS, Stephen, A.,B202 La Maison Apartments , WILLETTE, Robert, N. , AIYAR, Nambi, V. , ARNOLD, Anne, Romanic , KHANDOUDI, Nassirah , GOUT, Bernard , AL-BARAZANJI, Kamal , AMES, Robert, S. , FOLEY, James, J. , SARAU, Henry, M. , CHAMBERS, Jon , SHABON, Usman , BERGSMA, Derk, J.
CPC分类号： C07K14/705 , A61K38/00 , A61K48/00 , C07K14/723
摘要： Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of ischemic coronary artery disease (angina and myocardial infarction); atherosclerosis; metabolic diseases (e.g. diabetes); CHF/myocardial dysfunction; arrhythmias; restenosis; hypertension; hypotension; pulmonary disease (hypertension, COPD, asthma); fibrotic vasculopathies (diabetes, SLE, AS, Reynaud's); cerebrovascular events (e.g. hemnorrhagic and ischemic stroke); neurogenic inflammation/migraine; hematopoietic disorders; ARDS; cancer; autoimmune diseases (e.g. HIV-1 and -2 infection and AIDS); gastrointestinal and genitourinary disturbances (e.g. ulcers); endocrine disorders; fibroproliferative disorders (e.g. psoriasis); inflammatory disease (e.g. RA, Crohn's, IBS); benign prostatic hypertrophy; renal failure and glomerulopathies; disease states, both cardiovascular and non-cardiovascular, which are characterized by excessive vasoconstriction, myocardial dysfunction and/or aberrant fibroproliferative/inflammatory responses; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, Parkinson's disease, and dyskinesias, infections such as bacterial, fungal, protozoan and viral infections; pain; eating disorders, such as obesity, anorexia, and bulimia; asthma; urinary retention; oteoporosis; allergies; Huntington's disease or Gilles de la Tourette's syndrome, among others and diagnostic assays for such conditions.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.013 秒)
